Loading
Total declarations
Company
▲ Purchases (3 ops.)
▼ Sales (0 ops.)
Latest filing published 09 Oct 2020 for Mereo BioPharma Group plc, €13k.
Filing timeline
BuySaleJohn Richard
Insider track record
Disclosed buys
3
Disclosed sells
0
Signal history
Closed purchases
Market purchases
3
Positive at T+90
33%
Median T+90
-11.9%
Based on 3 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Purchases by company
Since each purchase
- -1.4%Entry US$2.14 · Close at T+365 US$2.11
- -16.3%Entry US$3.55 · Close at T+365 US$2.97
- -71.7%Entry US$4.45 · Close at T+365 US$1.26
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
John Richard: trading record in brief
This profile gathers the share dealings of John Richard in Mereo BioPharma Group plc. Over a trading history stretching from 21 May 2019 to 7 October 2020, the count stands at 5 filings.
The open-market record is one-sided, with 3 purchases worth €31k and not one sale. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Outside the open market, there are 2 share grants. Since January 2020: 1 purchase and no sales on the market.
A typical purchase (the median) is worth €13k. Of 3 purchases, 3 formed part of a group of insiders buying within 30 days of each other. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase. For 3 purchases whose 90-day window has closed, the share price was higher on day 90 than the day after publication in 33% of cases, with a median move of -11.9%. These figures describe past trades and do not predict future prices.
The latest filing, published on 9 October 2020, reports an open-market purchase of €13k in Mereo BioPharma Group plc. Filings reach the SEC (Form 4) feed a median of 1 day after the trade. For comparison, the SEC allows two business days to file a Form 4. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Companies and markets linked to John Richard
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations5 total
6,500 shares@ US$2.3642.5% of flowXNMSFCA-NSM:3744239-2
Canonical exit: 5 Jan 2021 (T+90)
1,500 shares@ US$3.31100.0% of flowXNMSFCA-NSM:LSE20190816135146_14192519_20200326185057228_19902-3
Canonical exit: 13 Nov 2019 (T+90)
27,500 sharesOutside of a trading venueFCA-NSM:LSE20190724100812_14161287_20200326185123408_10441-5
3,000 shares@ US$4.9074.7% of flowXNMSFCA-NSM:LSE20190523161135_14085741_20200326185141891_8374-2
Canonical exit: 20 Aug 2019 (T+90)
27,500 sharesOutside of a trading venueFCA-NSM:LSE20190521150839_14082298_20200326185142080_11482-5
5 of 5 declarations
